×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease

Study Represents Largest  DNA Mapping Effort Undertaken in U.S. from a Single Population

REYKJAVIK, ICELAND, and SALT LAKE  CITY – Intermountain Healthcare and  deCODE genetics have announced a major global collaboration and study focused  on discovering new connections between genetics and human disease that will  involve the collection of half a million DNA samples.

The initiative, called the  HerediGene: Population Study, represents the largest and most comprehensive DNA  mapping effort to date in the United States from a single population. For the  study, which is voluntary and free to participants, Intermountain teams will  work with deCODE to analyze the genomes of 500,000 people from Intermountain’s  patient population, primarily in Utah and Idaho.

Intermountain Healthcare is a  Utah-based not-for-profit integrated healthcare delivery network, and deCODE  Genetics is a wholly owned subsidiary of Amgen based in Reykjavik, Iceland. The  collaborative effort combines Intermountain’s internationally-recognized  expertise in precision medicine and clinical care with deCODE’s world-class  expertise in human population genetics.

“While the 500,000 samples will  be collected primarily from patients in Utah, the research is expected to have  a global impact as medications, treatments, and healthcare innovations that can  benefit patients universally are developed from the findings,” said Lincoln  Nadauld, MD, PhD, Intermountain’s chief of precision health. “The collaboration  is noteworthy and unique in its size, scope, and immediate application to  patient care.”

Participants in the study will  consent to the testing and have the option to receive their genetic results  report, if a clinically significant gene mutation is identified. The data will  be de-identified to ensure anonymity before it is utilized in research to help  medical professionals better understand the human genome, which will enhance  their ability to predict and prevent diseases such as breast cancer, colon  cancer, and heart disease.

“This  unique collaboration is expected to uncover new insights into some of society’s  most debilitating diseases,” noted Kári Stefánsson, MD, Dr. Med., founder and  chief executive officer of deCODE genetics. “Our partnership with Intermountain  Healthcare is important as we continue to identify and validate human disease  targets. These potential discoveries will allow deCODE and Amgen to rapidly  develop new medicines that reach the right disease targets.”

Intermountain will leverage its renowned  precision genomics efforts to improve patient outcomes and transform medicine. Intermountain’s  precision medicine team analyzes individual differences in genetics,  environments, and lifestyles and helps medical professionals specifically target  the illnesses of each patient and identify the treatments that will best help  them.

“Better health and being able to  cure common diseases is the promise of precision medicine, but it’s not  happening fast enough,” said Marc Harrison, MD, president and chief executive  officer at Intermountain Healthcare. “For too long, the genetic code to better  health has been locked. This collaboration with deCODE unlocks that insight so  we can rapidly advance well-being – not only for ourselves and our families,  but for generations to come.”

Insights from the collaboration may power  fundamental changes to better understand the human genome, improve health, and  prevent common diseases.

For more information on the study, please go to  Intermountainhealthcare.org/heredigene.

About deCODE genetics
Based in Reykjavik, Iceland,  deCODE is a global leader in analyzing and understanding the human genome.  Using its unique expertise and population resources, deCODE has discovered  genetic risk factors for dozens of common diseases. Understanding the genetics  of disease can create new means of diagnosing, treating and preventing disease.  deCODE is a wholly-owned subsidiary of Amgen.

About Intermountain
  Intermountain Healthcare is a  Utah-based not-for-profit system of 24 hospitals, 160 clinics, a Medical Group  with some 2,300 employed physicians and advanced care practitioners, a health  insurance company called SelectHealth, and other health services. Intermountain  is widely recognized as a leader in transforming healthcare through  evidence-based best practices, high quality, and sustainable costs. For more  information about Intermountain, visit intermountainhealthcare.org.

Amgen Forward-Looking Statements
  This news release contains  forward-looking statements that are based on the current expectations and  beliefs of Amgen. All statements, other than statements of historical fact, are  statements that could be deemed forward-looking statements, including estimates  of revenues, operating margins, capital expenditures, cash, other financial  metrics, expected legal, arbitration, political, regulatory or clinical results  or practices, customer and prescriber patterns or practices, reimbursement  activities and outcomes and other such estimates and results. Forward-looking  statements involve significant risks and uncertainties, including those  discussed below and more fully described in the Securities and Exchange  Commission reports filed by Amgen, including its most recent annual report on  Form 10-K and any subsequent periodic reports on Form 10-Q and current reports  on Form 8-K. Unless otherwise noted, Amgen is providing this information as of  the date of this news release and does not undertake any obligation to update  any forward-looking statements contained in this document as a result of new  information, future events or otherwise.

No forward-looking statement can  be guaranteed, and actual results may differ materially from those Amgen  project. Amgen’s results may be affected by its ability to successfully market  both new and existing products domestically and internationally, clinical and  regulatory developments involving current and future products, sales growth of  recently launched products, competition from other products including  biosimilars, difficulties or delays in manufacturing its products and global  economic conditions. In addition, sales of Amgen’s products are affected by  pricing pressure, political and public scrutiny and reimbursement policies  imposed by third-party payers, including governments, private insurance plans  and managed care providers and may be affected by regulatory, clinical and  guideline developments and domestic and international trends toward managed  care and healthcare cost containment. Furthermore, Amgen’s research, testing,  pricing, marketing and other operations are subject to extensive regulation by  domestic and foreign government regulatory authorities. Amgen or others could  identify safety, side effects or manufacturing problems with its products,  including its devices, after they are on the market. Amgen’s business may be  impacted by government investigations, litigation and product liability claims.  In addition, Amgen’s business may be impacted by the adoption of new tax  legislation or exposure to additional tax liabilities. If we fail to meet the  compliance obligations in the corporate integrity agreement between us and the  U.S. government, we could become subject to significant sanctions.  Further, while Amgen routinely obtains  patents for its products and technology, the protection offered by its patents  and patent applications may be challenged, invalidated or circumvented by its  competitors, or Amgen may fail to prevail in present and future intellectual  property litigation. Amgen performs a substantial amount of its commercial manufacturing  activities at a few key facilities, including in Puerto Rico, and also depends  on third parties for a portion of its manufacturing activities, and limits on  supply may constrain sales of certain of its current products and product  candidate development. In addition, Amgen competes with other companies with  respect to many of its marketed products as well as for the discovery and  development of new products. Discovery or identification of new product  candidates or development of new indications for existing products cannot be  guaranteed and movement from concept to product is uncertain; consequently,  there can be no guarantee that any particular product candidate or development  of a new indication for an existing product will be successful and become a  commercial product. Further, some raw materials, medical devices and component  parts for Amgen’s products are supplied by sole third-party suppliers. Certain  of Amgen’s distributors, customers and payers have substantial purchasing  leverage in their dealings with Amgen. The discovery of significant problems  with a product similar to one of Amgen’s products that implicate an entire  class of products could have a material adverse effect on sales of the affected  products and on its business and results of operations. Amgen’s efforts to  acquire other companies or products and to integrate the operations of  companies Amgen has acquired may not be successful. A breakdown, cyberattack or  information security breach could compromise the confidentiality, integrity and  availability of Amgen’s systems and Amgen’s data. Amgen’s stock price may be  volatile and may be affected by a number of events. Amgen’s business  performance could affect or limit the ability of the Amgen Board of Directors  to declare a dividend or its ability to pay a dividend or repurchase its common  stock. Amgen may not be able to access the capital and credit markets on terms  that are favorable to it, or at all.

The scientific information  discussed in this news release related to Amgen’s product candidates is  preliminary and investigative. Such product candidates are not approved by the  U.S. Food and Drug Administration, and no conclusions can or should be drawn  regarding the safety or effectiveness of the product candidates. Further, the  scientific information discussed in this news release relating to new  indications for Amgen’s products is preliminary and investigative and is not  part of the labeling approved by the U.S. Food and Drug Administration for the  products. The products are not approved for the investigational use(s)  discussed in this news release, and no conclusions can or should be drawn  regarding the safety or effectiveness of the products for these uses.

Media Contacts:
Intermountain Healthcare:                                                       deCODE  genetics:
Brad Gillman:  brad.gillman@imail.org/385-315-8949          Jon Gustafsson: jon@decode.is/+354 664 1905